182 reports of this reaction
2.1% of all DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN reports
#9 most reported adverse reaction
SOMNOLENCE is the #9 most commonly reported adverse reaction for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, manufactured by RB Health (US) LLC. There are 182 FDA adverse event reports linking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN to SOMNOLENCE. This represents approximately 2.1% of all 8,751 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 182 FDA reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 2.1% of all adverse event reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, making it a notable side effect.
If you experience somnolence while taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.